Heart rate control: Betablockers or Ivabradine therapy before cardiac computed tomography

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522741-21-00

Enrollment

350

Registered

2025-10-01

Start date

2025-12-09

Completion date

Unknown

Last updated

2025-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic heart disease

Brief summary

The primary end point measure is the time to a heart rate (mean) lowered by 10% from baseline after adminstration of study drug

Interventions

DRUGIVABRADINE

DRUGATENOLOL

DRUGMETOPROLOL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary end point measure is the time to a heart rate (mean) lowered by 10% from baseline after adminstration of study drug	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026